Lighting the torch: intratumoural T cell-to-stroma enrichment score as a predictor of immunotherapy response in urothelial carcinoma

Nat Rev Clin Oncol. 2024 Jul;21(7):487-488. doi: 10.1038/s41571-024-00890-2.

Authors

David H Aggen¹, Jonathan E Rosenberg²

Affiliations

¹ Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
² Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. [email protected].

PMID: 38622410
DOI: 10.1038/s41571-024-00890-2

No abstract available

MeSH terms

Carcinoma, Transitional Cell / drug therapy
Carcinoma, Transitional Cell / immunology
Carcinoma, Transitional Cell / pathology
Carcinoma, Transitional Cell / therapy
Humans
Immunotherapy* / methods
Stromal Cells / pathology
T-Lymphocytes* / immunology
Tumor Microenvironment / immunology
Urinary Bladder Neoplasms* / drug therapy
Urinary Bladder Neoplasms* / immunology
Urinary Bladder Neoplasms* / pathology
Urinary Bladder Neoplasms* / therapy